Sign in
Wet AMD 3 Symposium
Annual Meeting Talks
2020
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021
Intravitreal Gene Therapy for Neovascular AMD With ADVM-022: Results of the Phase 1 OPTIC Trial
Charles C Wykoff, MD, PhD, FASRS
Category: AMD-Neovascular